Latest Content

A sBLA seeking the approval of zenocutuzumab has been submitted to the FDA, and the agent was added to the NCCN guidelines for NRG1-positive cholangiocarcinoma.

Christian Capitini has been named the next director of the University of Wisconsin Carbone Cancer Center.

In a recent Peer Exchange, breast and lung cancer experts discussed comprehensive strategies for identifying and mitigating the AEs associated with ADCs.

Aaron Gerds, MD, details the rationale behind investigating agents targeting CALR mutations and other novel therapies in myeloproliferative neoplasms.

Alicia Morgans, MD, MPH, and Michael Schweizer, MD, discuss the phase 3 MEVPRO-1 and MEVPRO-2 trials of mevrometostat plus enzalutamide in mCRPC.

Mayo Clinic researchers developed an experimental nanotherapy that delivers two cancer drugs directly to brain tumors.

The NCCN updated its 2026 Guidelines for breast cancer screening and diagnosis to include an AI-based risk assessment tool to predict breast cancer risk.

Metronomic treatment approaches could represent therapeutic avenues for patients with TP53-mutated myeloid malignancies.

The CSF-1R–targeting monoclonal antibody emactuzumab met key end points in the phase 3 TANGENT study, setting the stage for a BLA submission.

Frontline darovasertib plus crizotinib generated a PFS improvement vs treatment of investigator’s choice in HLA-A*02:01–negative metastatic uveal melanoma.

Sac-TMT plus pembrolizumab was safe and effective in recurrent/metastatic cervical cancer.

Tisotumab vedotin plus carboplatin & pembrolizumab ± bevacizumab achieved 65.8% ORR and 28-month median OS in first-line recurrent/metastatic cervical cancer.

Mirvetuximab soravtansine plus carboplatin showed antitumor activity and a manageable safety profile in patients with recurrent platinum-sensitive ovarian cancer.